Powder Flow Studies II

Gold, Gerald; Duvall, Ronald N.; Palermo, Blaze T.; Slater, James G.

doi:10.1002/jps.2600551125

Cited by 48 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final crystals are needleshaped ( Figure S7) and flow poorly, which results in inconsistent tablet composition from fluctuations in the gravimetric powder feeder. Poor flowability is often solved by adding a glidant, [23] in our case SiO 2 (2.5 wt % on a dry basis). This is typically done late in the formulation process; however, that would require metering SiO 2 at 1.15 g h À1 , which is well outside the capabilities of commercial powder feeders.…”

mentioning

confidence: 99%

End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

et al. 2013

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The final crystals are needle‐shaped (Figure S7) and flow poorly, which results in inconsistent tablet composition from fluctuations in the gravimetric powder feeder. Poor flowability is often solved by adding a glidant,23 in our case SiO 2 (2.5 wt % on a dry basis). This is typically done late in the formulation process; however, that would require metering SiO 2 at 1.15 g h −1 , which is well outside the capabilities of commercial powder feeders.…”

Section: Methodsmentioning

confidence: 99%

End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…[24] This is the maximum angle possible between the surface of a pile of powder or granules and the horizontal plane. [25] It is the easiest and most commonly used test for powder flowability.…”

Section: Methodsmentioning

confidence: 99%

Influence of excipients and processing conditions on the development of agglomerates of racecadotril by crystallo-co-agglomeration

Garala

Patel

et al. 2012

Int J Pharma Investig

View full text Add to dashboard Cite

Purpose:The purpose of the present investigation was to improve the flow and mechanical properties of racecadotril by a crystallo-co-agglomeration (CCA) technique. Direct tableting is a requirement of pharmaceutical industries. Poor mechanical properties of crystalline drug particles require wet granulation which is uneconomical, laborious, and tedious.Materials and Methods:The objective of this work was to study the influence of various polymers/excipients and processing conditions on the formation of directly compressible agglomerates of the water-insoluble drug, racecadotril, an antidiarrheal agent. The agglomerates of racecadotril were prepared using dichloromethane (DCM)–water as the crystallization system. DCM acted as a good solvent for racecadotril as well as a bridging liquid for the agglomeration of the crystallized drug and water as the nonsolvent. The prepared agglomerates were tested for micromeritic and mechanical properties.Results:The process yielded ~90 to 96% wt/ wt spherical agglomerates containing racecadotril with the diameter between 299 and 521 μ. A higher rotational speed of crystallization system reduces the size of the agglomerates and disturbs the sphericity. Spherical agglomerates were generated with a uniform dispersion of the crystallized drug. CCA showed excellent flowability and crushing strength.Conclusion:Excipients and processing conditions can play a key role in preparing spherical agglomerates of racecadotril by CCA, an excellent alternative to the wet granulation process to prepare intermediates for direct compression.

show abstract

Powder Flow Studies II

Cited by 48 publications

References 10 publications

End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

End‐to‐End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

Influence of excipients and processing conditions on the development of agglomerates of racecadotril by crystallo-co-agglomeration

Contact Info

Product

Resources

About